Press Releases

BC3 TECHNOLOGIES’ SEAL HEMOSTATIC WOUND SPRAY NAMED WINNER OF 2025 EMS WORLD INNOVATION AWARD

Baltimore, MD

December 5, 2025

BC3 TECHNOLOGIES’ SEAL HEMOSTATIC WOUND SPRAY NAMED WINNER OF 2025 EMS WORLD INNOVATION AWARD

-- Industry-Leading Hemorrhage Control Product Recognized for Advancing Prehospital Trauma Care --

(Baltimore, MD) – BC3 Technologies, a Baltimore-based, minority-owned company revolutionizing emergency medical response and trauma care, announces today that its SEAL Hemostatic Wound Spray has been named a 2025 EMS World Innovation Award winner by EMS World, recognizing groundbreaking products that are transforming prehospital care.

The EMS World Innovation Awards honor the most pioneering products of the year that demonstrate measurable impact, improved patient outcomes, and advancement of EMS practice. SEAL was selected for its first-of-its-kind FDA-cleared aerosolized chitosan delivery system designed for rapid assist in controlling severe external bleeding in the prehospital environment.

“We are deeply honored that SEAL has been recognized by EMS World as a 2025 Innovation Award winner,” shared Wayne Grube, CEO and Co-Founder, BC3 Technologies. “For decades, severe bleed control has relied primarily on pressure, gauze, and tourniquets. While those tools remain essential, the industry has long needed an innovative advancement that allows providers to respond faster and more effectively in challenging environments. This award validates that EMS leaders recognize the importance of evolving hemorrhage control. When seconds determine survival, innovation matters.”

Severe bleeding remains one of the leading causes of preventable death in trauma. EMS clinicians frequently operate in unpredictable, low-light, wet, or windy conditions where traditional bandage- or granule-based hemostatic products can be difficult to deploy quickly. SEAL Hemostatic Wound Spray was designed to meet these challenges through a compact aerosolized delivery system that rapidly disperses medical-grade chitosan across the wound surface, forming a physical barrier that assists in hemorrhage control when used in conjunction with direct pressure.

SEAL is the first and only FDA-cleared aerosolized chitosan product for rapid management of serious external bleeding. This patented innovation represents a significant advancement in emergency response, offering fast, effective application even in adverse environments. Its dry-powder aerosol design allows rapid surface coverage of irregular wounds, making it particularly useful in complex or multi-casualty settings where speed is critical. Compact and easy to carry, SEAL can be administered by first responders, medical professionals, military personnel, trained caregivers, and prepared civilians. SEAL Pro is available in a 2.5 oz single-use spray and SEAL OTC in a 1.5 oz single-use spray. BC3 Technologies also offers supporting accessories, including first aid kits and SEAL holders, to enable rapid deployment in the field and during everyday emergencies.

The recognition from EMS World further reinforces SEAL’s growing adoption among EMS systems, fire departments, law enforcement agencies, and military units domestically and internationally. As agencies seek improved tools to bridge the gap between injury and definitive care, innovative hemorrhage control solutions like SEAL are expanding the tools available within established trauma response protocols.

“This award is bigger than BC3 Technologies,” added Grube. “It represents a shift in how the EMS community is thinking about bleed control. Innovation in this space hasn’t meaningfully changed in over 20 years. We are proud to be part of moving the industry forward and helping providers save more lives in the field.”

About BC3 Technologies (www.bc3tech.com)
Founded in Baltimore in 2018, BC3 Technologies is a minority-owned company revolutionizing emergency medical response and trauma care. A privately held medical device company, BC3 Technologies focuses on the development and commercialization of hemostatic products that help save lives. Fueled by the recognition of a critical gap in emergency medical care and the urgent need for efficient management of life-threatening complex bleeding, the company designed its patented technology in the first and only FDA-cleared chitosan aerosol hemostatic wound spray, SEAL. Today, SEAL is being utilized by first responders, in surgical environments, in battlefield combat, and by everyday heroes globally.

BC3 Technologies’ mission is to enhance the survivability and recovery of individuals experiencing severe bleeding, whether in a medical facility, on the battlefield, or in everyday emergencies.

# # #